Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO [3]. - Defendants are accused of making public statements that were materially false and misleading, which were negligently prepared [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States [5].
Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO